Objective:
Report long-term outcomes of MCO-010 in patients with advanced retinitis pigmentosa (RP).
Approach:
- Therapy: MCO-010 is an optogenetic therapy delivered by intravitreal injection. It aims to make retinal bipolar cells light-sensitive when photoreceptors are absent.
- Study: The presentation described findings from the RESTORE trial at the 2026 AAO Meeting.
Key Findings:
- The presenter reported that MCO-010 met trial endpoints, including gains in visual acuity, mobility, and shape discrimination.
- Efficacy was reported as maintained over three years.
- The presenter described safety as encouraging, with no significant side effects noted.
Interpretation:
The presenter characterized MCO-010 as a potential treatment option for patients with very advanced RP.
Limitations:
- The context does not provide trial design, participant numbers, quantitative outcome data, or detailed adverse-event results.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







